Kathy D. Miller

Kathy D. Miller's AcademicInfluence.com Rankings

Kathy D. Miller

Medical

#3098

World Rank

#3553

Historical Rank

Oncology

#211

World Rank

#219

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Kathy D. Miller Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kathy D. Miller's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. (2007) (2993)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. (2005) (1308)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. (2007) (896)
NF-κ B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4* (2003) (674)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. (2008) (611)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. (2008) (481)
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. (2003) (479)
Redefining the target: chemotherapeutics as antiangiogenics. (2001) (408)
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. (2013) (334)
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. (2012) (332)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. (2018) (297)
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. (2009) (281)
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells (2005) (277)
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). (2011) (265)
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. (2014) (252)
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. (2003) (237)
Comparison of younger and older breast cancer survivors and age‐matched controls on specific and overall quality of life domains (2014) (195)
Angiogenesis of breast cancer. (2005) (188)
A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer (2005) (182)
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer (2017) (180)
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy (2013) (166)
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy (2013) (159)
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). (2015) (158)
Thermoacoustic molecular imaging of small animals. (2003) (156)
Exploiting the hallmarks of cancer: the future conquest of breast cancer. (2003) (147)
Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer (2006) (140)
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial (2018) (134)
Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. (1997) (133)
E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. (2003) (131)
Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer (2006) (127)
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer (2009) (127)
Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. (1999) (120)
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer (2016) (116)
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. (2003) (115)
A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). (2010) (113)
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. (2020) (113)
Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. (2020) (112)
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. (2021) (108)
Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents. (2006) (105)
Predicting fear of breast cancer recurrence and self-efficacy in survivors by age at diagnosis. (2012) (97)
Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (2005) (95)
Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. (2000) (95)
Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 (2015) (91)
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. (2018) (89)
Randomized controlled pilot trial of mindfulness-based stress reduction compared to psychoeducational support for persistently fatigued breast and colorectal cancer survivors (2016) (88)
Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. (2006) (88)
Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue (2007) (87)
The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer (2009) (86)
An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations (2018) (84)
Clinical-Translational Approaches to the Nm23-H1 Metastasis Suppressor (2008) (82)
Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. (2020) (77)
EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. (2003) (77)
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy (2017) (75)
Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. (2002) (73)
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. (2014) (71)
Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer (2020) (69)
Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. (2014) (68)
A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer (2004) (68)
Thermoacoustic CT: imaging principles (2000) (67)
Can tumor angiogenesis be inhibited without resistance? (2005) (65)
Interleukin-1α promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer (2003) (64)
The role of chemotherapy for metastatic breast cancer. (1999) (64)
The implementation of an oncologist referred, exercise self‐management program for older breast cancer survivors (2006) (64)
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer (2017) (63)
Cognitive appraisals, coping and depressive symptoms in breast cancer patients. (2012) (62)
Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer (2007) (61)
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. (2016) (61)
A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen (2005) (60)
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. (2002) (60)
A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors (2012) (60)
Synthesis of [11C]PBR06 and [18F]PBR06 as agents for positron emission tomographic (PET) imaging of the translocator protein (TSPO) (2011) (60)
Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial (2018) (59)
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure (2016) (58)
Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester. (2003) (57)
Depression in husbands of breast cancer patients: relationships to coping and social support (2011) (57)
Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3‐arm pilot randomized controlled trial (2019) (56)
Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. (2011) (54)
[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers. (2012) (54)
Role of RPL39 in Metaplastic Breast Cancer (2017) (51)
Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model (2006) (51)
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer (2009) (51)
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study (2018) (50)
Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC). (2009) (50)
Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer (2017) (50)
Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4'-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4'-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbutanamide. (2004) (48)
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. (2012) (47)
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131 (2021) (47)
Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial (2013) (47)
Health-Related Quality of Life of African American Breast Cancer Survivors Compared With Healthy African American Women (2012) (45)
Resistance in the anti-angiogenic era: nay-saying or a word of caution? (2003) (45)
Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. (2003) (45)
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146. (2015) (44)
Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103 (2014) (44)
Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. (2005) (44)
Angiogenesis as targeted breast cancer therapy. (2007) (43)
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). (2018) (43)
[11C]Choline as a potential PET marker for imaging of breast cancer athymic mice. (2002) (43)
Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104) (2008) (43)
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. (2003) (42)
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100 (2014) (41)
Thermoacoustic Molecular Imaging of Small Animals (2003) (41)
Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100) (2011) (40)
A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab. (2009) (40)
Taxanes in the treatment of breast cancer: a prodigy comes of age. (1999) (40)
Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer (2011) (39)
Abstract S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy (2017) (38)
Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. (2004) (37)
Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer (2018) (36)
Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory (2004) (36)
Developing DCE-CT to Quantify Intra-Tumor Heterogeneity in Breast Tumors With Differing Angiogenic Phenotype (2009) (36)
Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents. (2003) (35)
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer (2018) (35)
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) (2021) (34)
TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. (2020) (33)
The role of ErbB inhibitors in trastuzumab resistance. (2004) (33)
Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging. (2010) (33)
Phase I trial of metronomic oral vinorelbine in patients with advanced cancer (2011) (33)
TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis (2015) (32)
A Physiologic Imaging Pilot Study of Breast Cancer Treated with AZD2171 (2006) (32)
Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans (2016) (32)
Breast Cancer in a Wife: How Husbands Cope and How Well It Works (2011) (32)
Angiogenesis and antiangiogenic therapy. (2002) (32)
Synthesis of MMP inhibitor radiotracers [11C]methyl-CGS 27023A and its analogs, new potential PET breast cancer imaging agents (2002) (31)
The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3). (2011) (31)
64 Cu-MM-302 Positron Emission Tomography Quanti ﬁ es Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer (2017) (29)
A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). (2010) (29)
A brief intervention to minimize psychosexual morbidity in dyads coping with breast cancer. (2012) (29)
Photoacoustic spectroscopic imaging of intra-tumor heterogeneity and molecular identification (2006) (28)
Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. (2006) (28)
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109 (2013) (28)
Simple synthesis of carbon-11 labeled styryl dyes as new potential PET RNA-specific, living cell imaging probes. (2009) (28)
A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. (2014) (26)
Synthesis of radiolabeled stilbene derivatives as new potential PET probes for aryl hydrocarbon receptor in cancers. (2006) (25)
Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer (2015) (25)
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group (2021) (25)
Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast cancer. (2007) (24)
Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36). (2020) (24)
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC): Hoosier Oncology Group BRE09-146. (2014) (24)
Targeting progesterone signaling prevents metastatic ovarian cancer (2020) (24)
A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer. (2012) (23)
Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer. (2011) (23)
In vivo modeling of metastatic human high-grade serous ovarian cancer in mice (2020) (23)
Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. (2017) (23)
Recent translational research: antiangiogenic therapy for breast cancer – where do we stand? (2004) (22)
LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer (2020) (21)
Symptom experiences in metastatic breast cancer patients: relationships to activity engagement, value‐based living, and psychological inflexibility (2017) (21)
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen (2009) (21)
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. (2012) (21)
Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off. (2019) (21)
Synthesis of carbon-11-labeled 4-aryl-4H-chromens as new PET agents for imaging of apoptosis in cancer. (2010) (21)
A system for detecting high impact-low frequency mutations in primary tumors and metastases (2018) (20)
Comparison of younger and older breast cancer survivors and age-matched controls on specific and overall QoL domains (2014) (20)
A Phase II Study of 9-Nitro-Camptothecin in Patients with Previously Treated Metastatic Breast Cancer (2004) (20)
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients (2020) (19)
Phase II dose escalation trial of Avastin™ (bevacizumab) in women with previously treated metastatic breast cancer (2001) (19)
Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T) (2007) (18)
Survival benefit needed to undergo chemotherapy: Patient and physician preferences (2017) (18)
Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. (2019) (18)
Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial (2018) (18)
Synthesis of carbon-11 labeled celecoxib derivatives as new candidate PET radioligands for imaging of inflammation. (2009) (18)
Development of new targeted therapies for breast cancer. (2008) (18)
Synthesis of MMP inhibitor radiotracer [11C]CGS 25966, a new potential pet tumor imaging agent (2003) (18)
Metastatic breast cancer: the role of chemotherapy. (1999) (18)
Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy. (2010) (18)
Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in cancer. (2011) (17)
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers (2019) (17)
Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC). (2010) (17)
Breast cancer: the role of angiogenesis and antiangiogenic therapy. (2004) (17)
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. (2017) (17)
Design and synthesis of carbon-11-labeled dual aromatase–steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expression in breast cancer (2009) (17)
Synthesis of new carbon‐11‐labeled 7‐aroyl‐aminoindoline‐1‐sulfonamides as potential PET agents for imaging of tubulin polymerization in cancers (2008) (16)
Questioning Our APHINITY for More. (2017) (16)
Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer. (2008) (16)
Synthesis of radiolabeled O6‐benzylguanine derivatives as new potential PET tumor imaging agents for the DNA repair protein O6‐alkylguanine‐DNA alkyltransferase (2002) (16)
Issues and Challenges for Antiangiogenic Therapies (2002) (15)
Thermoacoustic CT scanner for breast imaging: design considerations (2000) (15)
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor – Positive , Human Epidermal Growth Factor Receptor 2 – Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy : Results of PrE 0102 (2018) (15)
Monitoring the Longitudinal Intra-tumor Physiological Impulse Response to VEGFR2 Blockade in Breast Tumors Using DCE-CT (2011) (14)
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609) (2021) (14)
The implications of insurance status on presentation, surgical management, and mortality among nonmetastatic breast cancer patients in Indiana☆ (2018) (14)
Abstract GS6-03: Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer (2018) (14)
PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). (2017) (14)
Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC) (2008) (14)
A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007 (2010) (14)
Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase. (2021) (14)
[11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C. (2011) (13)
Synthesis of 2-[11C]methoxy-3,17β-O,O-bis(sulfamoyl)estradiol as a new potential PET agent for imaging of steroid sulfatase (STS) in cancers (2012) (13)
Dual TGFβ/BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast (2019) (13)
Synthesis of 2,6-difluoro-N-(3-[11C]methoxy-1H-pyrazolo[3,4-b]pyridine-5-yl)-3-(propylsulfonamidio)benzamide as a new potential PET agent for imaging of B-Raf(V600E) in cancers. (2013) (13)
Triple negative breast cancer-review of current and emerging therapeutic strategies (2016) (13)
A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer. (2011) (13)
Adverse association of expressed vascular endothelial growth factor (VEGF) with long-term outcome of stage I-III breast cancer (BrCa), with co-expression data of VEGF and Her2, Cox2, uPA and ER. Results from the British Columbia Tissue Microarray Project. (2004) (13)
Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer. (2008) (13)
Antiangiogenic Agents in Breast Cancer (2007) (12)
1802 Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC) (2015) (12)
The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent. (2010) (12)
What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? (2015) (12)
Impact of primary breast cancer therapy on energetic capacity and body composition (2018) (12)
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. (2001) (12)
Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC (2021) (12)
Development of new targeted therapies for breast cancer (2008) (12)
Redefining the target again: chemotherapeutics as vascular disrupting agents? (2008) (12)
Synthesis of new carbon-11 labeled cyclofenil derivatives for PET imaging of breast cancer estrogen receptors. (2008) (12)
Determination of the maximum tolerated dose (MTD) of the CNS penetrant tyrosine kinase inhibitor (TKI) tesevatinib administered in combination with trastuzumab in HER2+ patients with metastatic breast cancer (BC). (2016) (12)
A Convenient Procedure for the Synthesis of O6-Benzylguanine Derivatives by Phase Transfer Catalysis (2003) (11)
Selection bias in clinical trials. (2001) (11)
Metastatic breast cancer patients’ expectations and priorities for symptom improvement (2018) (11)
TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker. (2019) (11)
Abstract GS5-02: Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158 (2020) (11)
Simple synthesis of carbon-11-labeled chromen-4-one derivatives as new potential PET agents for imaging of DNA-dependent protein kinase (DNA-PK) in cancer. (2012) (11)
The Potential and Suitability of 2-Methoxyestradiol in Cancer Therapy (2005) (11)
Phase II, open label study of SB-715992 (Ispinesib) in subjects with advanced or metastatic breast cancer (2005) (10)
Abstract P3-12-04: A phase 2, multi-center, open label study evaluating the efficacy and safety of GRN1005 alone or in combination with trastuzumab in patients with brain metastases from breast cancer (2012) (10)
Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy. (2017) (10)
Molecular imaging of neutropilin-1 receptor using photoacoustic spectroscopy in breast tumors (2010) (10)
Factors underlying metastatic breast cancer patients' perceptions of symptom importance: a qualitative analysis (2018) (10)
Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). (2021) (9)
Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers. (2005) (9)
Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer (2010) (9)
215TiPPALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer (2017) (9)
Synthesis, biodistribution and micro-PET imaging of radiolabeled antimitotic agent T138067 analogues. (2004) (9)
Thermoacoustic in vivo determination of blood oxygenation (2004) (9)
A pilot trial of itraconazole pharmacokinetics in patients with metastatic breast cancer. (2011) (9)
Arterial thromboembolic events and patients with metastatic carcinoma treated with chemotherapy and bevacizumab (Journal of the National Cancer Institute (2007) 99 (1232-1239)) (2008) (9)
Synthesis of radiolabeled protein disulfide isomerase (PDI) inhibitors as new potential PET agents for imaging of the enzyme PDI in neurological disorders and cancer. (2013) (8)
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer (2021) (8)
Breast cancer: challenges and opportunities. (1999) (8)
Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer (2021) (8)
Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells (2019) (8)
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. (2019) (8)
55PPET/CT IMAGING OF 64CU-LABELLED HER2 LIPOSOMAL DOXORUBICIN (64CU-MM-302) QUANTIFIES VARIABILITY OF LIPOSOMAL DRUG DELIVERY TO DIVERSE TUMOR LESIONS IN HER2-POSITIVE BREAST CANCER PATIENTS (2014) (8)
Are There Differences in Treatment and Survival Between Poor, Older Black and White Women with Breast Cancer? (2015) (8)
Targeted immunotherapy for HER2-low breast cancer with 17p loss (2021) (8)
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer (2008) (7)
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer (2021) (7)
Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer. (2018) (7)
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer (2022) (7)
Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. (2002) (7)
Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402). (2011) (7)
Synthesis of (Z)-2-((1H-indazol-3-yl)methylene)-6-[¹¹C]methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one as a new potential PET probe for imaging of the enzyme PIM1. (2013) (7)
Cardiovascular safety of adjuvant bevacizumab for breast cancer. (2010) (6)
Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer (2020) (6)
A Phase II Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma. (2019) (6)
Abstract GS6-05: The impact of breast cancer surgery on quality of life: Long term results from E5103 (2019) (6)
Toward Checkmate: Biology and Breast Cancer Therapy for the New Millennium (2004) (6)
Facile radiosynthesis of new carbon-11-labeled propanamide derivatives as selective androgen receptor modulator (SARM) radioligands for prostate cancer imaging (2011) (6)
Inhibiting fatty acid synthase in operable triple negative breast cancer. (2020) (6)
Abstract P4-12-29: Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancer (2013) (6)
SU11248 (sunitinib malate) therapy in patients with refractory metastatic breast cancer: preliminary safety and efficacy results from a phase II study (2006) (6)
Abstract OT3-06-02: An initial safety study of gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer (2019) (6)
A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma (2004) (6)
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03) (2022) (5)
Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer (2017) (5)
Synthesis of carbon-11-labeled tricyclic necroptosis inhibitors as new potential PET agents for imaging of tumor necrosis factor alpha (TNF-alpha). (2010) (5)
Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer. (2015) (5)
Primary Yolk Sac Tumor of the Rectum (2000) (5)
A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma (2000) (5)
Biomarker prediction of chemotherapy-related amenorrhea. (2013) (5)
Synthesis of new carbon-11 labeled naphthalene-sulfonamides for PET imaging of human CCR8. (2008) (5)
2107 POSTER Preliminary results of a phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer (2007) (5)
Facile synthesis of carbon-11-labeled cholesterol-based cationic lipids as new potential PET probes for imaging of gene delivery in cancer (2010) (5)
A Personalized, Dynamic Physical Activity Intervention Is Feasible and Improves Energetic Capacity, Energy Expenditure, and Quality of Life in Breast Cancer Survivors (2021) (5)
Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research (2022) (5)
PARP inhibition after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier Oncology Group BRE09-146. (2011) (4)
Abstract OT2-1-06: E2112: A randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer (2015) (4)
An Exploratory Study of the Biological Activity of Sunitinib as a Component of Neoadjuvant Therapy for Breast Cancer. (2009) (4)
Synthesis of carbon-11-labeled tariquidar derivatives as new PET agents for imaging of breast cancer resistance protein (ABCG2). (2010) (4)
HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-D (2015) (4)
Abstract OT1-03-21: PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer (2016) (4)
Abstract P3-14-05: Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer (2016) (4)
A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer. (2015) (4)
TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer. (2010) (4)
Abstract OT3-2-01: A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer (2013) (4)
A pilot study of vascular endothelial growth factor inhibition with bevacizumab in patients with lymphedema following breast cancer treatment. (2009) (4)
Synthesis of a New Carbon-11–Labeled Sulfamate Derivative as a Potential PET Tracer for Imaging of Breast Cancer Aromatase and Steroid Sulfatase Expression (2011) (4)
Clinical-Translational Approaches to the Nm23-H1 (2008) (3)
Abstract GS4-02: E2112: Randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group (2021) (3)
AMulticenter Phase II Trialof ZD 6474 , aVascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor , in Patientswith Previously TreatedMetastatic Breast Cancer (2005) (3)
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane-containing regimen: HOG BRE05–97 (2008) (3)
Abstract OT2-01-04: E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group (2016) (3)
Symptom burden and employment status in breast cancer (BC) survivors. (2018) (3)
Abstract P4-15-04: Effect of pre-treatment with cyclophosphamide on MM-302 (HER2-targeted liposomal doxorubicin) deposition in HER2-positive metastatic breast cancer patients assessed by64Cu-MM-302 PET/CT (2015) (3)
Impact of African ancestry on the relationship between body mass index and survival in an early‐stage breast cancer trial (ECOG‐ACRIN E5103) (2022) (3)
Abstract P1-03-01: An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer (2017) (3)
Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ (2021) (3)
A phase II study of oral MKC-1 for metastatic breast cancer (MBC) (2008) (3)
Synthesis of carbon-11 labeled biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues as new potential PET glioma tumor imaging agents. (2007) (3)
Incorporating the Oncotype DX breast cancer assay into community practice: an expert Q&A and case study sampling. (2008) (3)
Phase III Studies of Bevacizumab (B) in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC): Summary of Selected Adverse Events. (2009) (3)
Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). (2021) (3)
A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer. (2014) (3)
Comparison of Computational Algorithms for the Classification of Liver Cancer using SELDI Mass Spectrometry: A Case Study (2007) (3)
Abstract P5-18-13: Inhibiting telomerase to reverse trastuzumab (T) resistance in HER2+ breast cancer (2012) (3)
Does biomarker information impact breast cancer patients’ preferences and physician recommendation for adjuvant chemotherapy? (2017) (2)
High-dose chemotherapy in breast cancer -- the perils of history uncontrolled. (2000) (2)
Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers. (2020) (2)
Abstract OT3-05-08: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer (2018) (2)
Abstract P5-17-01: Bevacizumab (B) in the adjuvant treatment of breast cancer - first toxicity results from Eastern Cooperative Oncology Group trial E5103. (2012) (2)
Abstract OT3-01-01: HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastu (2016) (2)
OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer. (2011) (2)
Abstract P3-08-16: ER, PR and HER2 biomarkers in UK and Irish clinical breast cancer testing: analysis of results from >168,000 patients (2018) (2)
P2-18-02: Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel (T) and Trastuzumab (H) for Node Negative, HER2 Positive Breast Cancer (BCA). (2011) (2)
Cytochrome P450 Polymorphisms and their Relationship with Premature Ovarian Failure in Premenopausal Women with Breast Cancer Receiving Doxorubicin and Cyclophosphamide (2011) (2)
A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131 (2)
Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer. (2022) (2)
Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials. (2020) (2)
Abstract OT1-03-01: Inhibiting fatty acid synthase to improve efficacy of neoadjuvant chemotherapy (2020) (2)
Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (2022) (2)
Prospective study of magnetic resonance imaging (MRI) and multiparameter gene expression assay in ductal carcinoma in situ (DCIS): A trial of the ECOG-ACRIN Cancer Research Group (E4112). (2017) (2)
OT3-01-05: PARP Inhibition after Preoperative Chemotherapy in Patients with Triple-Negative Breast Cancer (TNBC) or Known BRCA 1/2 Mutations: Hoosier Oncology Group BRE09-146. (2011) (2)
Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer (2017) (2)
Abstract P6-12-04: Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer (2017) (2)
Expert Consultations in Breast Cancer: Critical Pathways and Clinical Decision Making (2000) (2)
A double-blind, randomized, placebo-controlled phase II study of the steroidal aromatase inhibitor exemestane with and without the isoform selective histone deacetylase inhibitor (HDACi) entinostat in metastatic breast cancer (MBC). (2010) (2)
Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T) (2007) (2)
Inflammatory breast cancer appearance at presentation is associated with overall survival (2021) (2)
Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC) (2017) (2)
Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer. (2020) (2)
A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+ metastatic breast cancer (MBC). (2015) (2)
Association of a compact 13-gene VEGF signature with OS in E2100. (2012) (2)
Phase II results of tasisulam-sodium in previously treated patients with metastatic breast cancer. (2012) (2)
Abstract P2-14-02: A Pilot Study of Vascular Endothelial Growth Factor Inhibition with Pazopanib in Patients (pts) with Lymphedema Following Breast Cancer Treatment (2010) (2)
Abstract PD5-06: Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study (2018) (2)
Abstract P6-13-01: Local excision without radiation for ductal carcinoma in situ: 12-year results from the ECOG E5194 study (2015) (2)
Abstract OT-13-02: Bracelet-1 (pre0113): A study to assess overall response rate by inducing an inflammatory phenotype in metastatic breast cancer with the oncolytic reovirus pelareorep in combination with anti-PD-L1 avelumab and paclitaxel (2021) (1)
EA5, novel EphA2-targeted monoclonal antibody, inhibits growth and metastasis in human breast cancer xenografts (2005) (1)
Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05) (2022) (1)
Incorporating the Oncotype DX breast cancer assay into community practice: An expert Q & A and case study sampling. (2008) (1)
Urgent hypertension as a biomarker for bevacizumab in the curative setting. (2018) (1)
596TiP Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours (2020) (1)
Quality of life difficulties in partners of young breast cancer survivors. (2016) (1)
Preliminary results of a phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer (2007) (1)
Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events (2021) (1)
Abstract OT2-01-17: A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC) (2017) (1)
A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors. (2020) (1)
Abstract PS10-26: An initial safety study of gedatolisib plus cofetuzumab pelidotin for metastatic triple-negative breast cancer (2021) (1)
Abstract CT207: Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors (2021) (1)
Association of Charcot-Marie-Tooth gene, SBF2, with taxane-induced peripheral neuropathy in African Americans. (2016) (1)
Abstract P3-10-13: Prognostic Value of Genomic Analysis after Neoadjuvant Chemotherapy for Breast Cancer (2010) (1)
Abstract P3-02-12: Impact of magnetic resonance imaging on conversion from wide local excision to mastectomy in patients with ductal carcinoma in situ: First results from the ECOG-ACRIN 4112 prospective study (2017) (1)
Abstract P3-07-25: Improved clinical outcomes on enzalutamide observed in patients with PREDICT AR+ triple-negative breast cancer: prognosis or prediction? (2016) (1)
TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker. (2014) (1)
Abstract PD10-09: Impact of insurance and socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer (2020) (1)
A pilot study of vascular endothelial growth factor inhibition with bevacizumab in patients with lymphedema following breast cancer treatment (2009) (1)
Evaluating the Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer-Is Not Worse Good Enough? (2020) (1)
Synthesis of MMP inhibitor radiotracers ( 11 C)methyl-CGS 27023A and its analogs, (2002) (1)
A phase II study of lonafarnib (LF) in patients with locally advanced and metastatic breast cancer (MBC): Hoosier Oncology Group BRE07-126. (2011) (1)
Abstract CT012: Phase I study of TAS-114 in combination with capecitabine in patients with advanced solid tumors (2018) (1)
Commentary Recent translational research: antiangiogenic therapy for breast cancer - where do we stand? (2004) (1)
Radiosynthesis of New Carbon-11-labeled Nimesulide Analogs as Potential PET SAER Tracers for Imaging of Aromatase Expression in Breast Cancer (2010) (1)
Abstract OT2-04-05: Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC) 44 trial (2020) (1)
Telomerase TemplateAntagonist GRN 163 L Disrupts Telomere Maintenance , Tumor Growth , andMetastasis of Breast Cancer (2006) (1)
HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1 (2016) (1)
P1-08-01: Survival in Metastatic Breast Cancer (MBC): No Evidence for Improved Survival Following Distant Recurrence after Adjuvant Chemotherapy. (2011) (1)
Abstract PD3-16: Clinical safety and efficacy of the aurora and angiogenic kinase inhibitor ENMD-2076 in previously treated, locally advanced or metastatic triple-negative breast cancer (2018) (1)
Adjuvant palbociclib for ER+ breast cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort (2022) (1)
Synthesis of carbon-11-labeled casimiroin analogues as new potential PET agents for imaging of quinone reductase 2 and aromatase expression in breast cancer (2010) (1)
Abstract P2-01-01: Next generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy (2016) (0)
Synthesis of carbon-11 labeled triphenylacetamides as novel potential PET melanoma cancer imaging agents (2006) (0)
Abstract P6-15-03: Inflammatory breast cancer (IBC) defined: Proposed common diagnostic criteria and scoring - Moving beyond the subjective ‘clinical diagnosis’ of IBC to advance research (2020) (0)
CCDC 294956: Experimental Crystal Structure Determination (2007) (0)
Nivolumab with chemotherapy as neoadjuvant treatment for inflammatory breast cancer. (2022) (0)
[11C]GSK2126458 and [18F]GSK2126458 as new PET agents for imaging of PI3K and mTOR in cancer (2012) (0)
Abstract P1-09-01: Beyond fatigue – The impact of breast cancer treatment on body composition and energy expenditure (2015) (0)
Abstract P4-10-02: Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy (2022) (0)
P07.02A PHASE II CLINICAL TRIAL OF ENMD-2076 IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: TRANSLATING A P53-BASED BIOMARKER FROM BENCH TO BEDSIDE (2013) (0)
Quantitative evaluation of HER2-mediated cellular uptake of the HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 suggests potential for treating HER2-intermediate tumors (2016) (0)
Predictors of surgery preference and quality of life in DCIS after breast MRI: A trial of the ECOG-ACRIN Cancer Research Group (E4112). (2021) (0)
Abstract P2-07-04: Molecular regulators of resistance and relapse in chemorefractory triple-negative breast cancers (2018) (0)
Abstract P3-05-26: Association of muscle mass and density with outcomes in patients with ER positive metastatic breast cancer: correlative analysis of ECOG-ACRIN 2112 (2023) (0)
Cancer Therapy : Clinical A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride ( KOS-1022 ; 17 DMAG ) in the Treatment of Advanced Solid Tumors (2012) (0)
Abstract GS3-06: GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer (2023) (0)
Adjuvant chemotherapy for tumors of one centimeter or less: The law of diminishing returns (2001) (0)
Abstract P5-16-02: Variance between experts and community practitioners in treatment of metastatic breast cancer (2018) (0)
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy (2017) (0)
P5-01-06: Gene Copy Number and Expression of TYMP and TYMS Are Predictive of Outcome in Breast Cancer Patients Treated with Capecitabine. (2011) (0)
Antiangiogenic therapy for breast cancer (2007) (0)
Carbon-11-labeled tariquidar derivatives as new PET agents for imaging of breast cancer resistance protein (2010) (0)
iMETx (Individualized Metabolic Rx): Pilot study of an environmental intervention to increase energy expenditure among breast cancer survivors. (2018) (0)
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer (2016) (0)
[11C]Enzastaurin as a new PET cancer imaging agent for protein kinase C (2011) (0)
Abstract P5-01-03: Ultrasensitive detection of minimal residual disease in patients treated for breast cancer (2020) (0)
Abstract PD9-10: BRE12-158: A post-neoadjuvant, randomized phase 2 trial of personalized therapy vs. treatment of physician’s choice for patients with residual triple negative breast cancer (2022) (0)
African American Breast Cancer Survivor Outcomes (2010) (0)
Abstract OT2-3-11: Tivozanib in combination with paclitaxel vs placebo with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer (2012) (0)
Abstract P2-08-23: TP53 mutation is a biomarker for prognosis in triple-negative breast cancer patients treated with post-neoadjuvant cisplatin (2016) (0)
Anastrozole is as effective as tamoxifen as first-line treatment for hormone receptor positive advanced breast cancer (2002) (0)
Gene expression combined with gene set enrichment analysis to identify markers of vinorelbine efficacy in breast cancer patients. (2012) (0)
Thymidilate synthase gene copy number as predictive marker of capecitabine efficacy in patients with breast cancer. (2011) (0)
Intrinsic radiomics phenotypes of DCI from breast DCE-MRI: demonstrating feasibility in interim analysis of the ECOG-ACRIN E4112 trial (2021) (0)
Indiana Center for Breast Cancer Research (2014) (0)
Abstract OT2-06-02: Phase 2 trial with safety-run in of gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive HER2 negative breast cancer (2020) (0)
Resistance to Antiangiogenic Agents (2006) (0)
Abstract P1-08-02: Cytochrome P450 reductase gene, POR, associated with paclitaxel induced peripheral neuropathy in patients of European ancestry from the adjuvant breast cancer trial, ECOG-ACRIN E5103 (2022) (0)
Abstract OT1-12-02: Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab (2022) (0)
Abstract OT1-18-08: Randomized phase II trial of pembrolizumab/carboplatin vs. carboplatin alone for breast cancer with chest wall recurrence: TBCRC044 (2022) (0)
TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer. (2023) (0)
iMETX (Individualized Metabolic RX): An environmental intervention to increase energy expenditure in breast cancer survivors. (2019) (0)
Abstract 711: Co-detection of circulating tumor DNA and RNA for enhanced detection of minimal residual disease in patients with chemorefractory triple-negative breast cancer (2020) (0)
Abstract PO-219: The implications of genetic ancestry and allostatic load on clinical outcomes in the ECOG-ACRIN adjuvant breast cancer trial E5103 (2022) (0)
Abstract PS14-04: A picture worth a thousand words - “classic” inflammatory breast cancer (IBC) appearance associated with overall survival (2021) (0)
RNA-sequencing of residual triple-negative breast cancers after neoadjuvant chemotherapy compared to matched pretreatment biopsies from the Hoosier Oncology Group trial BRE09-146. (2014) (0)
Abstract OT2-16-01: ONCX-NAV-G201: A phase 2, basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors: Triple-negative breast cancer cohort (trial in progress) (2023) (0)
Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer (2021) (0)
TITLE: Sensitive detection of minimal residual disease in patients treated for early- 1 stage breast cancer 2 (2020) (0)
Does biomarker information impact patients’ preferences for therapy? (2013) (0)
A TOOL FOR PERSONALIZED DECISION MAKING: A CLINICAL PREDICTION MODEL FOR ANTHRACYCLINE CARDIOTOXICITY IN EARLY STAGE BREAST CANCER (2018) (0)
News from the San Antonio Breast Cancer Symposium 2010 (2011) (0)
[11C]Ro 31-7453 (MKC-1) as a new PET cancer imaging agent involving multiple targets (2010) (0)
TU‐C‐220‐08: Assessing Intra‐Tumor Hemodynamics and Oxygen Concentration Using Photoacoustic Computed Tomography (2011) (0)
Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial (2022) (0)
Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044. (2021) (0)
Synthesis of a New Carbon‐11‐Labeled Sulfamate Derivative (I) as a Potential PET Tracer for Imaging of Breast Cancer Aromatase and Steroid Sulfatase Expression. (2011) (0)
Effect of bariatric surgery on breast tissue and biomarkers in obese women at increased risk for breast cancer. (2017) (0)
Abstract OT2-3-01: SGN-LIV1A: A phase 1 trial evaluating a novel antibody-drug conjugate in patients with LIV-1-positive breast cancer (2015) (0)
Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. (2009) (0)
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers (2019) (0)
Abstract P5-11-02: Survival benefit needed to undergo chemotherapy: Patients and physicians preferences (2016) (0)
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer (2018) (0)
Poster session 7. Clinical Studies – non-phase 1 (2013) (0)
Cytochrome P450 oxidoreductase, POR, associated with severe paclitaxel-induced peripheral neuropathy in patients of European ancestry from ECOG-ACRIN E5103. (2023) (0)
New carbon-11 labeled dual aromatase-steroid sulfatase inhibitors for PET imaging of aromatase and sulfatase in breast cancer (2009) (0)
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer (2018) (0)
Immunotherapy and chemotherapy combination for chest wall disease: TBCRC 044 trial. (2020) (0)
New carbon-11 labeled 4-aryl-4H-chromenes as PET agents for imaging of apoptosis (2009) (0)
Abstract P4-01-15: Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC) (2023) (0)
Abstract PO-172: Impact of African ancestry on the relationship between body mass index (BMI) and survival in early stage breast cancer: Retrospective analysis from E5103 (2020) (0)
Social determinants of health, genetic ancestry, and mortality in ECOG-ACRIN E5103. (2021) (0)
127TiP Phase II, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2− BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC) (2021) (0)
Abstract 5224: Tracking the longitudinal physiological and vascular morphology changes in response to anti-angiogenesis treatment in breast tumors (2010) (0)
Fear of Breast Cancer Recurrence in African-American and Caucasian Breast Cancer Survivors (2010) (0)
Abstract P4-21-40: In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors (2017) (0)
ECOG-ACRIN tomosynthesis mammographic imaging screening trial (EA1151). (2020) (0)
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study (2018) (0)
Abstract P4-14-07: Treatment patterns for metastatic hormone receptor-positive breast cancer: Comparing expert and community practice (2020) (0)
Abstract P1-12-01: Clinical impact of internet-based tools to help guide therapeutic decisions for metastatic breast cancer (MBC) (2013) (0)
Male Breast Cancer (2016) (0)
Abstract P6-07-08: Dual TGFβ/BMP inhibition allows in vitro expansion of multiple cell types from normal and cancerous breast (2018) (0)
Results of the safety run-in of gedatolisib plus talazoparib in advanced triple negative or BRCA 1/2 positive HER2 negative breast cancer. (2022) (0)
Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors. (2021) (0)
APhysiologic Imaging Pilot Study of Breast Cancer Treatedwith AZD 2171 (2005) (0)
A phase II study of medroxyprogesterone acetate (MPA) in patients (pts) with hormone receptor-negative (HR-) metastatic breast cancer (MBC): Translational Breast Cancer Research Consortium trial 007. (2010) (0)
Abstract LB-061: HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo (2016) (0)
Abstract OT-13-09: Translational breast cancer research consortium 044 trial: Randomized phase 2 study of pembrolizumab and carboplatin versus carboplatin alone for chest wall recurrence of breast cancer (2021) (0)
Abstract OT3-1-10: HERmione: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with physician's choice of chemotherapy plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer, previously treated with pe (2015) (0)
Impact of African ancestry on the relationship between BMI and survival in early stage breast cancer: Retrospective analysis from E5103. (2021) (0)
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial. (2021) (0)

This paper list is powered by the following services:

Other Resources About Kathy D. Miller

medicine.iu.edu

What Schools Are Affiliated With Kathy D. Miller?

Kathy D. Miller is affiliated with the following schools:

Medical University of Vienna
Poznań University of Medical Sciences
Indiana University Bloomington
Indiana University
Indiana University–Purdue University Indianapolis
Purdue University
Johns Hopkins University
Rush University
University of Miami
Duke University